Vitamin D3 and K2: why it's worth combining them and how to dose (2026)

Vitamin D3 is one of the most widely supplemented nutrients in Poland, but its history provides an important lesson about the complexity of biology. For years, supplementation of D3 without K2 was encouraged – and science is slowly revealing that this combination may be crucial for safety. Vitamin D3 increases calcium absorption, which is great for bones – but excess calcium in the blood must go to the right place, not to the walls of arteries. This is where vitamin K2 comes in, activating proteins that transport calcium to bones and prevent its deposition in blood vessels. This article explains the mechanism of synergy between D3 and K2, optimal dosing, and the most important drug interactions.

KEY INFORMATION
• Maresz (Integrative Medicine, 2015) described the mechanism of synergy between D3 and K2 through the proteins osteocalcin and MGP – D3 increases serum calcium, while K2 directs it to bones, not arteries.
• Recommended doses: D3 2000–4000 IU daily, K2-MK7 100–200 mcg daily (MK-7 has a 72-hour half-life vs 1-2 hours for MK-4).
• Vitamin D deficiency affects an estimated 90% of Poles in autumn and winter (NIH/EFSA regional data).
• Vitamin K2 may interfere with warfarin and other anticoagulants – medical consultation required.

How does vitamin D3 work and why is D3 alone not enough?

Vitamin D3 (cholecalciferol) is produced in the skin under the influence of UVB radiation or obtained from food (fatty fish, eggs, fortified products). In the liver, it is converted to 25(OH)D – the form measured in blood tests – and in the kidneys to calcitriol (1,25(OH)₂D) – the active hormonal form. Holick et al. (New England Journal of Medicine, 2007) described vitamin D as a steroid hormone affecting the expression of over 200 genes involved in immunity, calcium metabolism, muscle function, and cellular regulation.

The key effect of D3 is the increased absorption of calcium from the intestines – even by 30–40% when transitioning from deficiency to optimal levels. This is good news for bone density. However, calcium absorbed into the blood must be directed to the right places: to bones and teeth, not to the walls of arteries, heart valves, and soft tissues. Without the appropriate amount of vitamin K2, this 'transport' is disrupted, as K2 carboxylated proteins (osteocalcin, MGP) remain inactive. Maresz (Integrative Medicine, 2015) detailed this mechanism as a fundamental justification for combining D3 with K2.

Our observations: The belief that 'vitamin D3 is safe in any amount' is a misconception that popular supplementation has developed over the years. Long-term supplementation of D3 without K2 at doses above 2000 IU per day may theoretically accelerate vascular calcification in individuals with subclinical K2 deficiencies – although direct RCTs confirming this effect in the general population still do not exist. Caution and supplementation of K2 is, however, biologically justified.

Vitamin K2 – what is it and which form is the most effective?

Vitamin K2 (menaquinone) is a family of compounds designated as MK-n, where n is the number of isoprenoid residues in the side chain. The most important for humans are MK-4 (from animal food) and MK-7 (from fermented products, especially Japanese natto). Both forms activate the same vitamin K-dependent proteins but differ significantly in pharmacokinetics.

Schurgers et al. (Blood, 2007) compared MK-4 and MK-7 clinically and demonstrated that MK-7, after a dose of 100–360 mcg, achieves significantly higher and more sustained serum concentrations than MK-4 – with MK-7 having a half-life of 72 hours (3 days), while MK-4 lasts only 1–2 hours. This means that MK-7 effectively maintains the activation of K2-dependent proteins throughout the day, while MK-4 requires multiple dosing or extremely high doses (45 mg daily used in Japanese osteoporosis studies).

Practical conclusion: when choosing a K2 supplement, look for the form MK-7 in a dose 100–200 mcg daily. Check if the preparation contains K2 as menaquinone-7 (sometimes listed as MK7 or natto-derived K2). 'All-trans' MK-7 forms have higher bioavailability than 'cis' forms – high-quality supplements should provide this information.

What are the recommended doses of D3 and K2?

Dosing of vitamin D3 depends on the baseline concentration of 25(OH)D in serum – it is advisable to perform a test before supplementation to tailor the dose to individual deficiency. General guidelines for adults: at a concentration of 25(OH)D below 20 ng/ml (severe deficiency) – 4000–5000 IU daily for 3–6 months, then re-evaluation. At a concentration of 20–30 ng/ml – 2000–4000 IU daily. To maintain optimal levels (30–60 ng/ml) – 1000–2000 IU daily during autumn and winter. The upper safe limit according to EFSA is 4000 IU daily for adults without medical supervision.

For vitamin K2 (MK-7): standard support when supplementing D3 is 100–200 mcg MK-7 daily. In cases of osteoporosis or vascular calcification in the family history – higher doses of 200–400 mcg daily are used in clinical studies. Knapen et al. (Osteoporosis International, 2007) demonstrated that 180 mcg MK-7 daily for 3 years in postmenopausal women significantly improved bone mineral density and reduced spinal bone loss compared to placebo. K2 doses are safe for most individuals, except for those taking anticoagulants.

D3+K2 interactions with medications and contraindications

High doses of vitamin D3 (above 10,000 IU daily for a long time) can cause hypercalcemia – an increase in calcium levels in the blood, which manifests as nausea, weakness, polyuria, and in extreme cases, kidney damage. At doses of 2000–4000 IU daily in adults, the risk of hypercalcemia is minimal, but individuals with granulomatous diseases (sarcoidosis, tuberculosis), primary hyperparathyroidism, or calcium kidney stones should consult a doctor before supplementing D3.

Vitamin K2 and anticoagulants represent the most clinically significant interaction. Vitamin K antagonists (warfarin, acenocoumarol) work by blocking the activity of K-dependent clotting factors. Supplementing K2 may reduce the effectiveness of these medications and lower INR below the therapeutic range, increasing the risk of thrombosis. Anticoagulated patients should not supplement K2 without consulting a doctor and monitoring INR. If patients on warfarin wish to supplement K2, it is possible to stabilize the anticoagulant dose at a higher level with a constant supply of K2 – but this requires medical supervision.

Other medications interacting with D3: antiepileptic drugs (phenytoin, carbamazepine) accelerate D3 metabolism, increasing the need for higher doses. Orlistat (a weight loss drug) reduces D3 absorption. Long-term corticosteroids increase calcium excretion and reduce D3 effectiveness – during prolonged steroid therapy, supplementation of D3+K2+Ca is particularly important.

Vitamin D3+K2 and cardiovascular health – what do studies say?

Vascular calcification – the deposition of calcium in the walls of arteries – is a risk factor for heart attack and stroke, independent of cholesterol levels. MGP (Matrix Gla Protein) is the strongest natural inhibitor of vascular calcification, and its activation requires vitamin K2. The problem is that inactive MGP (undercarboxylated) is common in individuals with low K2 intake or during long-term warfarin therapy – and this inactive MGP correlates with increased cardiovascular risk.

Rotterdam Study (Geleijnse et al., Journal of Nutrition, 2004) – one of the largest epidemiological studies in this field – tracked 4807 participants for an average of 7.2 years and showed that higher intake of vitamin K2 (not K1) correlated with a 52% lower risk of severe aortic calcification and a 57% lower risk of death from coronary disease. These are observational data, but their scale and direction of effect are impressive.

Interventional study Knapen et al. (Thrombosis and Haemostasis, 2015) with supplementation of 180 mcg MK-7 for 3 years in healthy postmenopausal women showed that MK-7 reduced arterial stiffness (measured by pulse wave velocity) compared to placebo. The effect was particularly pronounced in women with high baseline levels of undercarboxylated MGP. The study provides mechanistic and clinical evidence that K2 not only acts on bones but actively protects vascular elasticity.

Vitamin D3, in turn, regulates blood pressure through the renin-angiotensin system and has anti-inflammatory properties in the vascular endothelium. Pilz et al. (Nutrients, 2012) in their review stated that low levels of 25(OH)D correlate with a higher risk of cardiovascular diseases, although interventional studies with D3 supplementation yield mixed results regarding hard endpoints (heart attack, stroke). The combination of D3+K2 has better biological justification for cardiovascular health than either vitamin used separately.

Who should particularly consider D3+K2 supplementation?

Vitamin D deficiency is common in Poland due to geography (low sun exposure for 6–7 months a year) and lifestyle (indoor work). Pilz et al. (Nutrients, 2012) it is estimated that over 90% of Europeans have vitamin D deficiency in winter (below 20 ng/ml), and in Poland, during autumn and winter, the problem particularly affects individuals over 50 years old, office workers, and women using UV filters year-round.

Groups particularly benefiting from D3+K2 supplementation: individuals over 50 (D3 production in the skin decreases by 70% between ages 20 and 70), postmenopausal women (risk of osteoporosis), individuals with cardiovascular diseases or in their prevention, patients on long-term steroid therapy, individuals with lactose intolerance or a vegan diet (limited sources of D3 and K2 from diet). Supplementing D3 without K2 in these groups is biologically suboptimal, and at doses above 2000 IU daily, using K2 becomes particularly justified. Individuals working remotely or spending most of their time indoors, regardless of age, have limited skin synthesis of D3 and should consider supplementation as a standard element of health prevention for at least 9 months of the year (September–May), rather than just a winter adjustment.

Magnesium is another essential component for activating vitamin D3. The enzymes converting cholecalciferol to active calcitriol are magnesium-dependent. With magnesium deficiency, D3 supplementation may be less effective or even ineffective. Uwitonze and Razzaque (American Journal of Clinical Nutrition, 2018) They have shown that magnesium regulates vitamin D metabolism and that up to 50% of the population taking D3 may have a magnesium deficiency that blocks its full action. This means that the optimal "stack" is D3 + K2 + Magnesium – three complementary mineral and vitamin components for bone, heart, and calcium metabolism health. Magnesium glycinate or citrate at a dose of 200–400 mg daily is a natural supplement to this set.

You can read more about omega-3 supplementation and synergy with fat-soluble vitamins in the article Omega-3 properties and dosage.

Frequently Asked Questions

Why should D3 and K2 be taken together?

D3 increases calcium absorption from the intestines, while K2 activates proteins (osteocalcin, MGP) that direct calcium to the bones and prevent its deposition in the arteries. Maresz (Integrative Medicine, 2015) described this synergy: D3 mobilizes calcium, K2 decides where it goes. Without K2, D3 supplementation can increase serum calcium levels without guaranteeing it reaches the bones.

How much vitamin D3 and K2 should be taken daily?

D3: 2000–4000 IU daily for adults (with a deficiency of 25(OH)D below 20 ng/ml), preferably with a fatty meal. K2 (MK-7): 100–200 mcg daily. When supplementing D3 above 2000 IU daily, K2 should be a standard addition. Knapen et al. (2007) confirmed the effectiveness of 180 mcg MK-7 daily for bone protection in postmenopausal women.

Which form of vitamin K2 is better – MK-4 or MK-7?

MK-7 – with a half-life of 72 hours, allows for once-daily dosing and maintains constant activation of K2-dependent proteins. MK-4 has a half-life of 1–2 hours and requires doses 1000 times higher (45 mg vs 100–200 mcg), making it impractical as a supplement compared to K2 from food.

Can D3+K2 be taken together with heart medications?

Vitamin K2 may weaken the effects of vitamin K antagonists (warfarin, acenocoumarol) as it competes for the same metabolic pathways. Anticoagulated individuals should not supplement K2 without consulting a doctor and monitoring INR. Vitamin D3 itself does not have clinical interactions with typical cardiology medications at doses of 2000–4000 IU.

How long does it take to see the effects of D3+K2?

The level of 25(OH)D in the blood rises to the optimal range after 4–8 weeks of supplementation. The carboxylation of osteocalcin (a marker of K2 activation) normalizes after 6–8 weeks of regular MK-7 supplementation. Effects on bone mineral density require 12–24 months, similar to calcium supplementation – these are processes of bone metabolism, not pharmacological action.

What should vitamin D3 be absorbed with?

With fat – absorption increases by 50% when taken with a fatty meal or a tablespoon of oil. Mulligan and Bhatt (Journal of Bone and Mineral Research, 2010) confirmed significantly higher levels of 25(OH)D when D3 is taken with fat. D3 in soft gel capsules with MCT oil is absorbed better than the dry form of tablets, especially in individuals with fat absorption disorders. An egg, nuts, avocado, fatty fish, or a tablespoon of hemp oil for breakfast is a simple way to increase the bioavailability of D3+K2 without the need to purchase special preparations.

Is it worth measuring vitamin D levels before supplementation?

Yes – testing 25(OH)D from blood (reimbursed or available privately for about 30–50 PLN) allows for adjusting the D3 dose to the individual condition. The correct target concentration is 30–60 ng/ml (75–150 nmol/L). Above 100 ng/ml (150 nmol/L), the risk of D3 toxicity (hypercalcemia) increases. A follow-up test is advisable after 3–4 months of supplementation to confirm the correction of deficiency and possibly adjust the dose to maintain optimal levels.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a physician, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04